Hillstream BioPharma appoints Kelly Anderson to board, audit committee chair

Canton Strategic Holdings, Inc.

Kelly Anderson appointed to Board effective May 9, 2023, replacing Leonard Mazur as audit committee chair.
Also joins compensation and nominating/governance committees; board size increased to five.
Over 25 years of public company finance/accounting experience; currently CEO of CXO Executive Solutions.
Previously senior finance roles at Mavenlink, Ener-Core, Fisker Automotive, and other firms; CPA in California.
Appointment fills vacancy created by board size increase; term expires at 2023 annual meeting.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kelly Anderson

Director

CNTN · Canton Strategic Holdings, Inc.

Effective: 2023-05-09
Filed: May 15, 2023, 7:59 PM ET

On May 9, 2023, the Board of Directors (the “Board”) of Hillstream BioPharma, Inc. (the “Company”) increased the size of the Board to five members and appointed Kelly Anderson as a member of the Board to fill the vacancy created by the increase in the size of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kelly Anderson was appointed as Director at Canton Strategic Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

On May 9, 2023, the Board of Directors (the “Board”) of Hillstream BioPharma, Inc. (the “Company”) increased the size of the Board to five members and appointed Kelly Anderson as a member of the Board to fill the vacancy created by the increase in the size of the Board.

View on SEC.gov

Canton Strategic Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-017343

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.